North America Systemic Aspergillosis and Systemic Candidasis Market Dynamics and Trends by 2027
Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027North America Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ( Voriconazole, Liposomal, Amphotericin B, Systemic Oral Azoles, Topical, Antifungal Agents, and Others ); Application ( Chronic, Pulmonary Aspergillosis (CPA), Allergic, Bronchopulmonary Aspergillosis (ABPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, and Others ); and Country
- Report Date : Mar 2021
- Report Code : TIPRE00020066
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 127
The Systemic Aspergillosis and Systemic Candidasis market in North America is expected to grow from US$ 2,423.82 million in 2019 to US$ 3,352.62 million by 2027. This represents a CAGR of 4.2% from 2020 to 2027.
The growth of the market in the region is expected to grow owing to rise in prevalence of fungal diseases, rising hospital acquired fungal infection. Additionally, presence of major players and well-developed regulatory policies are projected to drive the North American systemic aspergillosis and systemic candidasis market during the forecast period.
Candida Auris is a fungus that causes a serious global health threat. C. Auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. Auris for a long time, and C. Auris can persist on surfaces in healthcare environments. This can result in the spread of C. Auris between patients in healthcare facilities. According to a CDC report of 2021, U.S. cases of C. Auris have been found in patients who had recent stays in healthcare facilities in Egypt, India, Kenya, Kuwait, Pakistan, South Africa, South Korea, the United Arab Emirates, and Venezuela, which also have documented cases. Thus, this can be a hospital-acquired infection. The emergence of Candida Auris is considered as one of the most serious problems associated with nosocomial transmission and with infection control practices in the hospital environment. Moreover, Centers for Disease Control and Prevention (CDC) stated,560 cases of C. auris infections have been notified in the United States as 31 January 2019. Furthermore, execution of countermeasures to limit fungal infections in intensive care units (ICUs), cases continue to be reported, with a tendency to an endemic pattern. This reflects the ability of C. auris to persist in clinical environment, enabling its transmission within critical care setting. Other than Candida species, C. auris can colonize different anatomical sites (e.g., skin, axilla, rectum, stool) and contaminate the hospital equipment and surfaces, creating a vicious cycle of spreading, acquisition, and infection, particularly in ICUs.
Additionally, according to the NCBI report published in Jan 2020, the Increasing number of travels to foreign countries and exposure to healthcare in countries with extensive C. Auris transmission, as well as the higher flow of migrants, are factors that can contribute to the quick dissemination of this species. Further, a higher frequency of C. Auris was found in public hospitals in comparison to the private ones, which may be connected to overcrowding and compromised infection control measures.
US Systemic Aspergillosis and Systemic Candidasis Market Revenue and Forecast to 2027 (US$ Million)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
NORTH AMERICA SYSTEMIC ASPERGILLOSIS AND SYSTEMIC CANDIDASIS – MARKET SEGMENTATION
By Type
- Systemic Oral Azoles
- Voriconazole
- Liposomal Amphotericin B
- Topical Antifungal Agents
- Others
By Application
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Chronic Pulmonary Aspergillosis (CPA)
- Gastrointestinal Candidiasis
- Genitourinary Tract Candidiasis
- Others
By Country
- US
- Canada
- Mexico
Company Profiles
- Novartis AG
- Sanofi
- Pfizer Inc.
- Merck & Co., Inc.
- Bayer AG
- Astellas Pharma Inc.
- GlaxoSmithKline plc.
- Abbott
- Cipla Inc.
- Enzon Pharmaceuticals, Inc.
North America Systemic Aspergillosis and Systemic Candidasis Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 2,423.82 Million |
| Market Size by 2027 | US$ 3,352.62 Million |
| Global CAGR (2020 - 2027) | 4.2% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, Market Research
The research report delivered details on drivers and restraints, trends, and opportunities, along with strategic activities in the market. Previously, we were struggling to get reliable information.
Manager Medical Devices ManufacturingReason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
- Novartis AG
- Sanofi
- Pfizer Inc.
- Merck & Co., Inc.
- Bayer AG
- Astellas Pharma Inc.
- GlaxoSmithKline plc.
- Abbott
- Cipla Inc.
- Enzon Pharmaceuticals, Inc.
Get Free Sample For